Nuvectis Pharma, Inc. (NVCT) stock
NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$19.11−1.13 (-5.58%)
Close on Nov 16, 2026Market cap $622.63MP/E –Yield 0.00%
Nuvectis Pharma total assets
Total assets on the balance sheet at the end of each period.
Nuvectis Pharma's total assets was $22.38M at Jun 30, 2026. For fiscal 2025 it was $31.71M, up 70.4% from the year before. The highest annual figure on record is $31.71M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.71M | +70.4% |
| FY2024 | Dec 31, 2024 | $18.61M | -3.0% |
| FY2023 | Dec 31, 2023 | $19.19M | -6.0% |
| FY2022 | Dec 31, 2022 | $20.41M | +206.5% |
| FY2021 | Dec 31, 2021 | $6.66M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.38M | -17.1% |
| Q1 FY2026 | Mar 31, 2026 | $25.40M | -15.8% |
| Q4 FY2025 | Dec 31, 2025 | $31.71M | +70.4% |
| Q3 FY2025 | Sep 30, 2025 | $35.59M | +105.6% |
| Q2 FY2025 | Jun 30, 2025 | $27.01M | +47.6% |
| Q1 FY2025 | Mar 31, 2025 | $30.15M | +52.9% |
| Q4 FY2024 | Dec 31, 2024 | $18.61M | -3.0% |
| Q3 FY2024 | Sep 30, 2024 | $17.31M | -22.3% |
| Q2 FY2024 | Jun 30, 2024 | $18.30M | -26.6% |
| Q1 FY2024 | Mar 31, 2024 | $19.71M | +21.6% |
| Q4 FY2023 | Dec 31, 2023 | $19.19M | -6.0% |
| Q3 FY2023 | Sep 30, 2023 | $22.26M | -10.5% |
| Q2 FY2023 | Jun 30, 2023 | $24.94M | +75.2% |
| Q1 FY2023 | Mar 31, 2023 | $16.21M | -8.0% |
| Q4 FY2022 | Dec 31, 2022 | $20.41M | +206.5% |
| Q3 FY2022 | Sep 30, 2022 | $24.87M | – |
| Q2 FY2022 | Jun 30, 2022 | $14.24M | – |
| Q1 FY2022 | Mar 31, 2022 | $17.62M | – |
| Q4 FY2021 | Dec 31, 2021 | $6.66M | – |
See a number that looks wrong?